ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2021Guideline
- Prognostic factors in radiotherapy of anaplastic thyroid carcinoma: a single center study over 31 years.Radiation oncology (London, England) · 2023Trial
- DNA Damage and Repair in Thyroid Physiology and Disease.Endocrine reviews · 2026Review
- The risk of radiation necrosis from combined radiotherapy and BRAF inhibitor in lung adenocarcinoma brain metastases: a comprehensive review and future perspectives.Frontiers in oncology · 2026Review
- Impact of RAS-MAPK Pathway Genetic Alterations on Radiotherapy Response in Metastatic Lung Adenocarcinoma.JCO precision oncology · 2025Article
- DNA repair and the contribution to chemotherapy resistance.Genome medicine · 2025Review
- Unveiling radiobiological traits and therapeutic responses of BRAFJournal of experimental & clinical cancer research : CR · 2025Article
- SPRED3 regulates the NF-κB signaling pathway in thyroid cancer and promotes the proliferation.Scientific reports · 2024Article
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers.Cancer letters · 2024Article
- DNA repair in tumor radioresistance: insights from fruit flies genetics.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Targeted therapy for head and neck cancer: signaling pathways and clinical studies.Signal transduction and targeted therapy · 2023Review
- Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials.Genes & diseases · 2023Review
- The role of lactate metabolism-related LncRNAs in the prognosis, mutation, and tumor microenvironment of papillary thyroid cancer.Frontiers in endocrinology · 2023Article
- Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma.Molecular cancer research : MCR · 2022Article
- BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.Radiation oncology (London, England) · 2021Article
- Article
- Efficacy of adavosertib therapy against anaplastic thyroid cancer.Endocrine-related cancer · 2021Article
- Targeting Genome Stability in Melanoma-A New Approach to an Old Field.International journal of molecular sciences · 2021Review
- Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma.Oncology letters · 2021Article
Corrections and comments
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
purposeActivating BRAF mutations, most commonly BRAF EXPERIMENTAL
designImmunoblotting, neutral comet, immunocytochemistry, functional reporter, and clonogenic assays were used to analyze the outcome and molecular characteristics following radiotherapy with or without BRAF
resultsBRAF
conclusionsBRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.